FoodNov 5, 2025
Severn Peanut Company MIXED NUTS Roasted No Salt NET WT 8 OZ recall — FDA H-0146-2026
Undeclared Tree Nut. The firm discovered that Hazelnuts was not listed in the allergen statement
Class IIFDA: OngoingSevern Peanut Company LLC
Latest records
Latest recalls — page 125
The newest recall records with useful source details are listed here.
FoodNov 5, 2025
Jody's CaBOT CREAMERY SEA SALT CARAMEL CHEDDAR SWEET & CHEESY POPCORN recall — FDA H-0139-2026
Undeclared Peanuts. The firm received two complaints that the product contains peanuts which are not listed in the ingredient statement.
Class IIFDA: OngoingJody's Inc.
FoodNov 5, 2025
Severn Peanut Company MIXED NUTS Roasted & Salted NET WT 8 OZ recall — FDA H-0145-2026
Undeclared Tree Nut. The firm discovered that Hazelnuts was not listed in the allergen statement
Class IIFDA: OngoingSevern Peanut Company LLC
FoodNov 5, 2025
Weaver Nut Company 47518 - Nonpareil, Semi-Sweet Chocolate recall — FDA H-0135-2026
undeclared milk allergen
Class IFDA: OngoingWeaver Nut Company, Inc
FoodNov 5, 2025
Weaver Nut Company D2645 - Nonpareils, Semi-Sweet Chocolate recall — FDA H-0136-2026
undeclared milk allergen
Class IFDA: OngoingWeaver Nut Company, Inc
FoodNov 5, 2025
Doan's Dessert And Coffee Carrot Bundt Cake - Net Weight 4 lbs Contains: Wheat, Soy recall — FDA H-0137-2026
Undeclared allergen ingredient (Wheat) in Ready-to-eat frozen cakes.
Class IFDA: TerminatedDoan's Dessert And Coffee
FoodNov 5, 2025
Doan's Dessert And Coffee White Chocolate Coconut Bundt Cake - Net Weight 3 lbs 12 oz recall — FDA H-0138-2026
Undeclared allergen ingredient (Wheat) in Ready-to-eat frozen cakes.
Class IFDA: TerminatedDoan's Dessert And Coffee
FoodNov 5, 2025
Tai Foong USA Fusia Asian Inspirations brand Veggie Spring Rolls recall — FDA H-0143-2026
Undeclared shrimp
Class IFDA: TerminatedTai Foong USA Inc
DrugNov 5, 2025
Desipramine Hydrochloride Tablets, USP, 75 mg, 100 count bottle (NDC 23155-581-01) recall — FDA D-0110-2026
CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.
Class IIFDA: OngoingHeritage Pharmaceuticals Inc
DrugNov 5, 2025
Lisdexamfetamine Dimesylate Capsules, 30 mg, CII, 100-count bottle recall — FDA D-0146-2026
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25C, 60%RH) for Lisdexamfetamine…
Class IIFDA: OngoingSUN PHARMACEUTICAL INDUSTRIES INC
DrugNov 5, 2025
Lisdexamfetamine Dimesylate Capsules, 40 mg, CII, 100-count bottle recall — FDA D-0147-2026
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25C, 60%RH) for Lisdexamfetamine…
Class IIFDA: OngoingSUN PHARMACEUTICAL INDUSTRIES INC
DrugNov 5, 2025
Endo USA Everolimus tablets 10 mg, 28 tablets recall — FDA D-0141-2026
Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.
Class IIIFDA: OngoingEndo USA, Inc.
DrugNov 5, 2025
Duloxetine Delayed-Release Capsules, USP, 60 mg, a.) 90-count bottle (NDC: 51991-748-90) recall — FDA D-0100-2026
CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.
Class IIFDA: OngoingBreckenridge Pharmaceutical, Inc.
DrugNov 5, 2025
Lisdexamfetamine Dimesylate Capsules, 10 mg, CII, 100-count bottle recall — FDA D-0144-2026
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25C, 60%RH) for Lisdexamfetamine…
Class IIFDA: OngoingSUN PHARMACEUTICAL INDUSTRIES INC
DrugNov 5, 2025
Prazosin Hydrochloride, Capsules, USP, 5 mg recall — FDA D-0106-2026
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.
Class IIFDA: OngoingTeva Pharmaceuticals USA, Inc
DrugNov 5, 2025
Lisdexamfetamine Dimesylate Capsules, 20 mg, CII, 100-count bottle recall — FDA D-0145-2026
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25C, 60%RH) for Lisdexamfetamine…
Class IIFDA: OngoingSUN PHARMACEUTICAL INDUSTRIES INC
DrugNov 5, 2025
QuVa Pharma R.E.C.K recall — FDA D-0113-2026
Presence of Particulate Matter
Class IIFDA: OngoingQuVa Pharma, Inc.
DrugNov 5, 2025
Desipramine Hydrochloride Tablets, USP, 100 mg, 100 count bottle (NDC 23155-582-01) recall — FDA D-0111-2026
CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.
Class IIFDA: OngoingHeritage Pharmaceuticals Inc
DrugNov 5, 2025
Desipramine Hydrochloride Tablets, USP, 50 mg, 100 count bottle (NDC 23155-580-01) recall — FDA D-0109-2026
CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.
Class IIFDA: OngoingHeritage Pharmaceuticals Inc
DrugNov 5, 2025
Prazosin Hydrochloride, Capsules, USP, 1 mg, 100 capsules (10x10) cartons recall — FDA D-0101-2026
Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit
Class IIFDA: OngoingAmerisource Health Services LLC
DrugNov 5, 2025
Lisdexamfetamine Dimesylate Capsules, 70 mg, CII, 100-count bottle recall — FDA D-0150-2026
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25C, 60%RH) for Lisdexamfetamine…
Class IIFDA: OngoingSUN PHARMACEUTICAL INDUSTRIES INC
DrugNov 5, 2025
Desipramine Hydrochloride Tablets, USP, 10 mg, 100 - count bottle (NDC 23155-578-01) recall — FDA D-0107-2026
CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.
Class IIFDA: OngoingHeritage Pharmaceuticals Inc
DrugNov 5, 2025
Prazosin Hydrochloride, Capsules, USP, 2 mg, 100 capsules (10x10) cartons recall — FDA D-0102-2026
Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit
Class IIFDA: OngoingAmerisource Health Services LLC
DrugNov 5, 2025
Endo USA Everolimus tablets 2.5 mg, 28 tablets recall — FDA D-0142-2026
Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.
Class IIIFDA: OngoingEndo USA, Inc.
Browse by month
Recent recall archives
Browse recent months with enough recall history for useful comparison.
August 2026146 records · 4 categoriesJuly 2026369 records · 4 categoriesJune 2026373 records · 4 categoriesMay 2026336 records · 4 categoriesApril 2026407 records · 4 categoriesMarch 2026181 records · 4 categoriesFebruary 2026330 records · 4 categoriesJanuary 2026211 records · 4 categoriesDecember 2025382 records · 4 categoriesNovember 2025273 records · 4 categoriesOctober 2025141 records · 3 categoriesSeptember 2025117 records · 3 categories